ライフサイエンスコーパス: bone marrow failure

1 ysplasia and thus serves as a model of human bone marrow failure.

2 sociated with both cancer predisposition and bone marrow failure.

3 rombasthenia, myelofibrosis, and progressive bone marrow failure.

4 racranial hemorrhages), immunodeficiency and bone marrow failure.

5 y of hematopoietic stem cells as a cause for bone marrow failure.

6 es such as idiopathic pulmonary fibrosis and bone marrow failure.

7 uster, die prematurely because of congenital bone marrow failure.

8 onary fibrosis and successive generations by bone marrow failure.

9 l double-deficient mice rapidly precipitates bone marrow failure.

10 ity of combination therapy for patients with bone marrow failure.

11 eta overexpressing transgenic mouse model of bone marrow failure.

12 er associated with cancer predisposition and bone marrow failure.

13 s), leading to their rapid disappearance and bone marrow failure.

14 q- syndrome to a congenital syndrome causing bone marrow failure.

15 s and may represent genetic risk factors for bone marrow failure.

16 pneumonia but severe anemia due to complete bone marrow failure.

17 estruction of hematopoietic cells results in bone marrow failure.

18 A) is an immune-mediated and serious form of bone marrow failure.

19 zed by exocrine pancreatic insufficiency and bone marrow failure.

20 bility disorder characterized by progressive bone marrow failure.

21 2 in regulation of p53 tumor suppression and bone marrow failure.

22 at FAN1 mutations cause chemosensitivity and bone marrow failure.

23 repair of these ICL can lead to leukemia and bone marrow failure.

24 e duplicated aluY repeat, thereby preventing bone marrow failure.

25 e HSPC results in impaired hematopoiesis and bone marrow failure.

26 predisposition, developmental disorder, and bone marrow failure.

27 leading to their depletion and precipitating bone marrow failure.

28 n of Gli1(+) cells abolished BMF and rescued bone marrow failure.

29 yndrome that is characterized by progressive bone marrow failure.

30 B and T cell lymphopenia, and progression to bone marrow failure.

31 DC patients usually die of bone marrow failure.

32 n and hematopoietic cell death, resulting in bone marrow failure.

33 f apoptosis and eventual symptoms related to bone marrow failure.

34 enetic disorder characterized by progressive bone marrow failure, accelerated aging, and cancer predi

35 FA displays bone marrow failure, acute myeloid leukemia, and head an

36 ized by early-onset diabetes associated with bone marrow failure, affecting mostly the erythrocytic l

37 ction between progressing bone fragility and bone marrow failure after Pneumocystis lung infection in

38 es and IFN a/b receptor (IFrag(-/-)) develop bone marrow failure after Pneumocystis lung infection, w

39 p spontaneous hematologic sequelae including bone marrow failure, AML, MDS and complex random chromos

40 yndrome that is characterized by progressive bone marrow failure and a high risk of cancer.

41 ssociation with developmental abnormalities, bone marrow failure and a strong predisposition to cance

42 cts multiple systems and is characterized by bone marrow failure and a triad of abnormal skin pigment

43 nemia (FA) is characterized by a progressive bone marrow failure and an increased incidence of cancer

44 tures including mucocutaneous abnormalities, bone marrow failure and an increased predisposition to c

45 is a rare genetic disorder characterized by bone marrow failure and an increased risk for leukemia a

46 cessive disease characterized by progressive bone marrow failure and an increased susceptibility to c

47 ized by hypoproliferative phenotypes such as bone marrow failure and anemia early in life, followed b

48 ups experienced early lethality due to acute bone marrow failure and aplastic anemia.

49 ide new tools for combinatorial therapies in bone marrow failure and bone marrow cancers.

50 chman-Diamond syndrome (SDS) is an inherited bone marrow failure and cancer predisposition syndrome t

51 se dyskeratosis congenita (DC), an inherited bone marrow failure and cancer predisposition syndrome.

52 ia (FA), an inherited disorder that includes bone marrow failure and cancer predisposition, have incr

53 enomic instability disorder characterized by bone marrow failure and cancer predisposition.

54 s, the mechanisms underlying the progressive bone marrow failure and cancer susceptibility of Fanconi

55 Fanconi anemia is a cancer-prone inherited bone marrow failure and cancer susceptibility syndrome w

56 zed by congenital malformations, progressive bone marrow failure and cancer susceptibility.

57 emia, a hereditary disorder characterized by bone marrow failure and cancer.

58 genome instability syndrome characterized by bone marrow failure and cellular hypersensitivity to DNA

59 erogeneous genetic disorder characterized by bone marrow failure and complex congenital anomalies.

60 ecessive disorder characterized by pediatric bone marrow failure and congenital anomalies.

61 risomy 8 clones can persist in patients with bone marrow failure and expand following immunosuppressi

62 acterized by congenital defects, progressive bone marrow failure and heightened cancer susceptibility

63 pe tends to have a relatively early onset of bone marrow failure and hematologic malignancies.

64 ed for patients with dyskeratosis congenita, bone marrow failure and idiopathic pulmonary fibrosis.

65 a (FA) is a genetic disease characterized by bone marrow failure and increased cancer risk.

66 a multigenic recessive disease resulting in bone marrow failure and increased cancer susceptibility.

67 nd autosomal genetic disease associated with bone marrow failure and increased cancer, as well as sev

68 dult mice resulted in acute lethality due to bone marrow failure and intestinal atrophy featuring ste

69 n Schwachman-Bodian-Diamond syndrome-a human bone marrow failure and leukaemia pre-disposition condit

70 Shwachman-Diamond syndrome, characterized by bone marrow failure and leukemia predisposition, is caus

71 h risk of developmental abnormalities, early bone marrow failure and leukemia.

72 mutated in hematologic malignancies such as bone marrow failure and leukemia.

73 at spindle instability in SDS contributes to bone marrow failure and leukemogenesis.

74 rus (KSHV) infection of bone marrow cells to bone marrow failure and lymphoproliferative syndromes.

75 We analyzed a patient with mild bone marrow failure and microcephaly who did not present

76 ve been implicated in the pathophysiology of bone marrow failure and myelodysplastic syndromes (MDS).

77 chronic inflammation and the development of bone marrow failure and myeloproliferative neoplasms.

78 cing was performed in three index cases with bone marrow failure and neurological dysfunction and who

79 n, has reached adulthood without the typical bone marrow failure and paediatric cancers.

80 plasmacytic lymphoproliferative disorders to bone marrow failure and peripheral cytopenias, associate

81 Older humans experience increased bone marrow failure and poorer haematologic tolerance of

82 This results in progressive bone marrow failure and predisposes to acute myeloid leu

83 ility, congenital malformations, progressive bone marrow failure and predisposition to hematologic ma

84 th a variety of developmental abnormalities, bone marrow failure and predisposition to leukemia and o

85 mia (FA), a genetic disorder associated with bone marrow failure and progression to leukemia and othe

86 We examined whether the cooccurrence of bone marrow failure and pulmonary fibrosis in the same i

87 diseases including various forms of cancer, bone marrow failure and pulmonary fibrosis.

88 disorder Fanconi anemia (FA) are progressive bone marrow failure and susceptibility to cancer.

89 ow that Trp53 is responsible for ICL-induced bone marrow failure and that loss of Trp53 is leukemogen

90 sessed subsequent hematotoxicity in terms of bone marrow failure and the ability to tolerate addition

91 arious congenital abnormalities, progressive bone marrow failure, and cancer predisposition.

92 s characterized by congenital abnormalities, bone marrow failure, and cancer predisposition.

93 e characterized by congenital abnormalities, bone marrow failure, and cancer susceptibility.

94 e characterized by congenital abnormalities, bone marrow failure, and cancer susceptibility.

95 essive disease marked by congenital defects, bone marrow failure, and cancer susceptibility.

96 eases such as idiopathic pulmonary fibrosis, bone marrow failure, and cryptogenic liver cirrhosis.

97 y multiple congenital anomalies, progressive bone marrow failure, and high cancer risk.

98 essive disease marked by congenital defects, bone marrow failure, and high incidence of leukemia and

99 r characterized by congenital abnormalities, bone marrow failure, and increased susceptibility to can

100 r characterized by congenital abnormalities, bone marrow failure, and marked cancer susceptibility.

101 r characterized by congenital abnormalities, bone marrow failure, and myeloid malignancies.

102 e characterized by congenital abnormalities, bone marrow failure, and susceptibility to leukemia and

103 ling in HSCs is found in two mouse models of bone marrow failure, and they show that treatment with r

104 sorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis.

105 zed by congenital abnormalities, progressive bone-marrow failure, and cancer susceptibility.

106 provide a mechanism for androgen therapy in bone marrow failure: androgens appear to regulate telome

107 Osteoporosis and bone marrow failure are additional unexplained complicat

108 Together, these data show that bone loss and bone marrow failure are partially linked, which suggests

109 mostly associated with inherited or acquired bone marrow failure, are believed to drive disease by sl

110 pendent of disease activity markers suggests bone marrow failure as a potential pathogenic factor in

111 disease, not only in myeloid cancers but in bone marrow failure as well.

112 of DC, including hyperpigmentation and fatal bone marrow failure at 4-5 mo of age.

113 Five (15%) of 34 patients developed bone marrow failure at a median 23 months (range, 6 to 5

114 eases, thrombohemorrhagic complications, and bone marrow failure because of myelofibrosis and leukemi

115 ns in the FANC genes and is characterized by bone marrow failure, birth defects, and a high incidence

116 oni anemia is a genetic disease resulting in bone marrow failure, birth defects, and cancer that is t

117 s congenita (DC) is a rare inherited form of bone marrow failure (BMF) caused by mutations in telomer

118 repair disorder characterized by progressive bone marrow failure (BMF) from hematopoietic stem and pr

119 The mechanism of bone marrow failure (BMF) in paroxysmal nocturnal hemogl

120 Although acquired bone marrow failure (BMF) is considered a T cell-mediate

121 Although acquired bone marrow failure (BMF) is considered a T cell-mediate

122 utosomal recessive condition associated with bone marrow failure (BMF) leading to death or hematopoie

123 An improved understanding of the bone marrow failure (BMF) mechanisms in Fanconi anemia (

124 A substantial number of individuals with bone marrow failure (BMF) present with one or more extra

125 The inherited bone marrow failure (BMF) syndromes are a rare and diver

126 s with high-risk hematologic malignancies or bone marrow failure (BMF) who received haploidentical bo

127 alities, chromosome instability, progressive bone marrow failure (BMF), and a strong predisposition t

128 a is characterized by a mucocutaneous triad, bone marrow failure (BMF), and presence of short telomer

129 es in 2 siblings presenting with progressive bone marrow failure (BMF), immunodeficiency, and develop

130 have been associated with the development of bone marrow failure (BMF).

131 (FA) is the most frequent inherited cause of bone marrow failure (BMF).

132 e thrombocytopenia progressing to trilineage bone marrow failure (BMF).

133 ortality from this disease is usually due to bone marrow failure, but idiopathic pulmonary fibrosis a

134 associated with nail dystrophy, leucoplakia, bone marrow failure, cancer predisposition and other fea

135 Fanconi anemia (FA) is a genetic disease of bone marrow failure, cancer susceptibility, and sensitiv

136 is a rare genetic disorder characterized by bone marrow failure, congenital abnormalities, and an in

137 is a rare genetic disorder that can lead to bone marrow failure, congenital abnormalities, and incre

138 These mice rapidly succumbed to fatal bone marrow failure, demonstrating that Srsf2-mutated ce

139 Fanconi anemia (FA) patients exhibit bone marrow failure, developmental defects and cancer.

140 as, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond-Blackfan an

141 Fanconi anemia (FA) is an inherited bone marrow failure disorder associated with a high inci

142 Dyskeratosis congenita (DC) is an inherited bone marrow failure disorder characterized by abnormal s

143 Diamond-Blackfan Anemia (DBA) is a bone marrow failure disorder characterized by low red bl

144 ditary breast and ovarian cancers as well as bone marrow failure disorder Fanconi anemia (FA).

145 aplastic anemia (SAA) is a life-threatening bone marrow failure disorder that can be treated with bo

146 mal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolyt

147 Fanconi anemia (FA) is a rare bone marrow failure disorder with defective DNA interstr

148 ance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indic

149 led to the idea that this and perhaps other bone marrow failure disorders result from an inadequate

150 cell transplantation for selected congenital bone marrow failure disorders, emphasis is now being pla

151 In the treatment of congenital bone marrow failure disorders, the goals are to eliminat

152 s with DC as well as 244 patients with other bone marrow failure disorders.

153 etween patients with DC and those with other bone marrow failure disorders.

154 ble engraftment rates for several congenital bone marrow failure disorders.

155 ults in depletion of germ cells and complete bone marrow failure due to increased apoptosis, culminat

156 ve defects and die prematurely from complete bone marrow failure due to the activation of an ATR-depe

157 ations in telomerase complex genes can cause bone marrow failure, dyskeratosis congenita, and acquire

158 utosomal recessive disorder characterized by bone marrow failure, exocrine pancreatic dysfunction, an

159 iated aplastic anemia (HAA) is a syndrome of bone marrow failure following an acute attack of seroneg

160 receptor (IFrag(-/-)) developed progressive bone marrow failure following infection, while lymphocyt

161 topoiesis in vivo in a novel murine model of bone marrow failure generated by constitutive hepatic ex

162 e and perhaps even direct the search for new bone marrow failure genes.

163 with LIG4 mutations, pancytopenia leading to bone marrow failure has not been observed.

164 By 2 weeks, in addition to bone marrow failure, he had evidence of alopecia and muc

165 (DC), an inherited syndrome characterized by bone marrow failure, hyperpigmentation, and nail dystrop

166 of isolated anemia, the pathogenesis of true bone marrow failure (i.e., low bone marrow cellularity a

167 and a broad range of pathologies, including bone marrow failure, immunodeficiency, and developmental

168 on, responsible for the primary induction of bone marrow failure in a subset of AA and MDS patients.

169 eper understanding of the molecular basis of bone marrow failure in FA and the cellular role of RAD51

170 ng DNA repair, the mechanisms underlying the bone marrow failure in FA patients are poorly defined.

171 ematopoiesis may underlie the progression to bone marrow failure in FA.

172 Therefore, the emergence of bone marrow failure in Fanconi anaemia is probably due t

173 ations for understanding the pathogenesis of bone marrow failure in Fanconi anemia and suggest possib

174 underlying molecular mechanisms that promote bone marrow failure in Fanconi anemia are incompletely u

175 as a critical factor in the pathogenesis of bone marrow failure in Fanconi anemia.

176 ced by progressive stem cell loss leading to bone marrow failure in hereditary dyskeratosis congenita

177 at somatic deletion of Recql4 causes a rapid bone marrow failure in mice that involves cells from acr

178 al observations and laboratory evidence link bone marrow failure in myelodysplastic syndrome (MDS) to

179 observations and experimental evidence link bone marrow failure in myelodysplastic syndrome (MDS) wi

180 lure followed by apoptosis may contribute to bone marrow failure in patients with FA.

181 opoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA)

182 We assessed the rate of bone marrow failure in patients with prostate cancer who

183 ells is decreased, reflecting a component of bone marrow failure in PNH.

184 eptor signaling could only partially prevent bone marrow failure in response to Pneumocystis infectio

185 personal and research protocol experience of bone marrow failure in the Hematology Branch of the Nati

186 lead to telomere shortening and progressive bone marrow failure in the premature aging syndrome dysk

187 ed to rare human disorders that present with bone marrow failure including Fanconi anemia (FA).

188 n studies to produce some characteristics of bone marrow failure, including a proliferative advantage

189 dyskeratosis congenita (DC) characterized by bone marrow failure, intrauterine growth retardation, de

190 Progressive bone marrow failure is a major cause of morbidity and mo

191 Bone marrow failure is a nearly universal complication o

192 Congenital bone marrow failure is rare and multifactorial.

193 acterized by mucocutaneous abnormalities and bone marrow failure, is caused by inherited defects in t

194 ere variant of DC in which an early onset of bone marrow failure leading to combined immunodeficiency

195 cts in telomere maintenance and repair cause bone marrow failure, liver cirrhosis, and pulmonary fibr

196 te the molecular pathogenesis of spontaneous bone marrow failure, MDS and AML in FA.

197 sence of wildtype support cells succumbed to bone marrow failure (median survival, 328 days) characte

198 osomal instability syndrome characterized by bone marrow failure, myelodysplasia (MDS), and acute mye

199 lop hematologic complications such as severe bone marrow failure, myelodysplastic syndrome, or acute

200 , n = 32; beta-thalassemia major, n = 6; and bone marrow failure, n = 5) were analyzed: median age, 1

201 echanism might explain why birth defects and bone marrow failure occur in Fanconi anemia, and may hav

202 his phenomenon is demonstrated by congenital bone marrow failure occurring in DNA-PKcs(3A/3A) mutant

203 to the heightened cancer predisposition and bone marrow failure of individuals with mutated FA prote

204 baseline cytopenias and develop spontaneous bone marrow failure or diverse hematologic malignancies

205 haematopoiesis and immunity in patients with bone marrow failure or hematological malignancies.

206 ed in telomere maintenance will be linked to bone marrow failure or other human diseases.

207 be associated with hematopoietic exhaustion, bone marrow failure, or even oncogenic transformation.

208 of Tak1(-/-) HSPCs and partially repress the bone marrow failure phenotype of Tak1(-/-) mice.

209 estriction (IUGR) with gonadal, adrenal, and bone marrow failure, predisposition to infections, and h

210 infection accelerated osteoclastogenesis as bone marrow failure progressed.

211 nearly always self-limited in patients with bone marrow failure receiving immunosuppression; differe

212 or older with thrombocytopenia secondary to bone marrow failure, requiring prophylactic platelet tra

213 In addition, regenerative bone marrow failure resulting in pancytopenia is another

214 stem, which phenocopied the highly penetrant bone marrow failure seen in Fanconi anaemia patients.

215 increased apoptosis, thus recapitulating the bone marrow failure seen in MDS.

216 congenita (X-DC), a disease characterized by bone marrow failure, skin abnormalities, and increased s

217 as been implicated in the pathophysiology of bone marrow failure states, we determined whether pharma

218 ome (SDS) (OMIM #260400) is a rare inherited bone marrow failure syndrome (IBMFS) that is primarily c

219 ct disease categories: a classical inherited bone marrow failure syndrome and a 'ribosomopathy'.

220 eratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition

221 Fanconi anemia (FA) is an inherited bone marrow failure syndrome associated with a progressi

222 wachman-Diamond syndrome (SDS), an inherited bone marrow failure syndrome associated with leukemia pr

223 ribosomal subunit maturation to an inherited bone marrow failure syndrome associated with leukemia pr

224 Dyskeratosis congenita, an inherited bone marrow failure syndrome associated with mucocutaneo

225 this reverse transcriptase is mutated in the bone marrow failure syndrome autosomal dominant dyskerat

226 to dyskeratosis congenita (DC), an inherited bone marrow failure syndrome caused by defects in telome

227 linked dyskeratosis congenita (DC) is a rare bone marrow failure syndrome caused by mostly missense m

228 amond Blackfan anaemia (DBA) is a congenital bone marrow failure syndrome characterised by selective

229 Dyskeratosis congenita (DC) is a multisystem bone marrow failure syndrome characterized by a triad of

230 Dyskeratosis congenita (DC) is a multisystem bone marrow failure syndrome characterized by a triad of

231 Diamond-Blackfan anemia (DBA), an inherited bone marrow failure syndrome characterized by anemia tha

232 Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized by chromosoma

233 Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome characterized by cutaneous

234 iamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by erythroid

235 iamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by erythroid

236 TERT and hTR cause dyskeratosis congenita, a bone marrow failure syndrome characterized by mucocutane

237 iamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell a

238 The two genes mutated in the bone marrow failure syndrome dyskeratosis congenita (DC)

239 an gene encoding dyskerin cause the skin and bone marrow failure syndrome dyskeratosis congenita (DC)

240 The progressive bone marrow failure syndrome dyskeratosis congenita (DC)

241 erase deficiency in the X-linked form of the bone marrow failure syndrome dyskeratosis congenita, mut

242 Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome in which the known suscepti

243 congenital neutropenia (CN) is a preleukemic bone marrow failure syndrome with a 20% risk of evolving

244 In addition to being an inherited bone marrow failure syndrome, DBA is also categorized as

245 gy to create a mouse model for the inherited bone marrow failure syndrome, DBA.The result, while reca

246 ability, including the most common inherited bone marrow failure syndrome, Fanconi anaemia.

247 is congenita (DC), a heterogeneous inherited bone marrow failure syndrome, have abnormalities in telo

248 nd syndrome (SDS; OMIM 260400), an inherited bone marrow failure syndrome, is caused by mutations in

249 eratosis congenita (AD DC), a rare inherited bone marrow failure syndrome, is caused by mutations in

250 of Shwachman-Diamond syndrome, an inherited bone marrow failure syndrome.

251 keratosis congenita (DC) is a rare inherited bone marrow failure syndrome.

252 fan anemia (DBA) is a cancer-prone inherited bone marrow failure syndrome.

253 Aplastic anaemia is a bone-marrow-failure syndrome characterised by low blood-

254 vely, these observations identify a distinct bone-marrow-failure syndrome due to mutations in ERCC6L2

255 Diamond-Blackfan anemia (DBA), a congenital bone-marrow-failure syndrome, is characterized by red bl

256 me synthesis may contribute to each of these bone marrow failure syndromes (and perhaps others), prec

257 PURPOSE OF REVIEW: Inherited bone marrow failure syndromes (IBMFS) are a diverse set

258 ome of CD34 cells derived from patients with bone marrow failure syndromes and identified characteris

259 sm of clonal selection and leukemogenesis in bone marrow failure syndromes and our data suggest that

260 The inherited bone marrow failure syndromes are clinically distinct bu

261 have recently shown that some patients with bone marrow failure syndromes are heterozygous carriers

262 Inherited bone marrow failure syndromes are human conditions in wh

263 Patients with inherited bone marrow failure syndromes are usually identified whe

264 Mutations in ribosomal proteins cause bone marrow failure syndromes associated with increased

265 Gene products mutated in the inherited bone marrow failure syndromes dyskeratosis congenita (DC

266 nifestations of telomere disease include the bone marrow failure syndromes dyskeratosis congenita and

267 riptase, telomerase, are associated with the bone marrow failure syndromes dyskeratosis congenita, ap

268 Other bone marrow failure syndromes have been attributed to de

269 ng their contributions to the development of bone marrow failure syndromes in Tak1-knockout mice (Tak

270 tibody-based immunosuppressive treatment for bone marrow failure syndromes in the absence of transpla

271 addition of SDS to the growing list of human bone marrow failure syndromes involving the ribosome.

272 ggests that expanded study in PRCA and other bone marrow failure syndromes is warranted.

273 emia at older age is complex and ranges from bone marrow failure syndromes to chronic kidney disease,

274 Androgens have been used in the treatment of bone marrow failure syndromes without a clear understand

275 for certain aspects of the pathology seen in bone marrow failure syndromes, including aplastic anemia

276 stic anemia, the paradigm of immune-mediated bone marrow failure syndromes, is characterized by hemat

277 Like most other bone marrow failure syndromes, it is associated with a m

278 needed to identify genes causally related to bone marrow failure syndromes, myelodysplastic syndromes

279 e development of hematologic malignancies or bone marrow failure syndromes.

280 d to define the relationship between PNH and bone marrow failure syndromes.

281 s in the 5q-syndrome, DBA, and perhaps other bone marrow failure syndromes.

282 rited and acquired red cell disorders and in bone marrow failure syndromes.

283 ologic disease, is the paradigm of the human bone marrow failure syndromes.

284 A DRB1 locus is a marker for immune-mediated bone marrow failure syndromes.

285 lar causes have been recognized to result in bone marrow failure syndromes: (1) defects in the Fancon

286 -Hreidarsson syndrome (HHS), are multisystem bone-marrow-failure syndromes in which the principal pat

287 ngenita, a complex syndrome characterized by bone marrow failure, telomerase enzyme deficiency, and p

288 a (AA) and myelodysplasia (MDS) are forms of bone marrow failure that are often part of the same prog

289 gamma-irradiation, Parp-2-/- mice exhibited bone marrow failure that correlated with reduced long-te

290 of certain FA mutations might play a role in bone marrow failure that frequently occurred in FA.

291 e molecular details of FA, the origin of the bone marrow failure that is central to this condition fo

292 Bone marrow failure was prevented by the reconstitution

293 unusual among primary immunodeficiencies and bone marrow failures, was due to a blockade in the bone

294 velop a Fanconi Anemia murine model to study bone marrow failure, we found that Fancd2(-/-) mice have

295 ly lethal, and deletion in adult mice led to bone marrow failure whereas parenchymal organs composed

296 Approximately 50% of patients with bone marrow failure who have clinical evidence of PNH at

297 Patients with bone marrow failure who have PNH cells detected by high-

298 strain induces a proliferative disorder and bone marrow failure with evidence of nonlymphoid neoplas

299 , a rare congenital disease characterized by bone marrow failure with neutropenia, exocrine pancreati

300 No patients developed bone marrow failure within 6 months of receiving stronti